ABIVAX Société Anonyme (EPA:ABVX)
France
· Delayed Price · Currency is EUR 95.55
-1.10 (-1.14%)
Apr 28, 2026, 5:35 PM CET
ABIVAX Société Anonyme Company Description
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease.
The company was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme
| Country | France |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Marc M. de Garidel |
Contact Details
Address: 7-11 Boulevard Haussmann Paris, 75009 France | |
| Phone | 33 1 53 83 09 63 |
| Website | abivax.com |
Stock Details
| Ticker Symbol | ABVX |
| Exchange | Euronext Paris |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR0012333284 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel M.B.A. | Chief Executive Officer and Director |
| Didier Blondel | EVice President, Chief Financial Officer and Board Secretary |
| Patrick Malloy | Senior Vice President of Investor Relations |
| Ida Hatoum | Chief People and Compliance Officer |
| Pierre Courteille M.B.A. | Chief Business Officer |
| Jerome Denis Ph.D. | Executive Vice President of Process Development and Manufacturing |
| Hema Keshava | Senior Vice President of Finance |
| Chris Rabbat Ph.D. | Vice President and Global Head of Medical Affairs |
| Kevin Shan Ph.D. | Vice President and Global Head of Biometrics |
| Mary Mantock | Senior Vice President and Global Head of Regulatory Affairs |